• DiscoveryProbe Protease Inhibitor Library: Mechanistic Insig

  2026-07-02

  Explore the DiscoveryProbe Protease Inhibitor Library's advanced role in protease inhibition research, with a deep dive into mechanistic innovations and practical assay optimization. This article uniquely integrates recent molecular insights to guide high-throughput and high-content screening decisions.

• AI-Derived Prognostic Signature Refines HCC Risk Stratificat

  2026-07-01

  This large-scale, multi-center study introduces a consensus artificial intelligence-derived prognostic signature (CAIPS) that outperforms traditional methods in predicting outcomes for hepatocellular carcinoma (HCC) patients. Integrating diverse machine learning algorithms, CAIPS enables robust risk stratification and guides targeted therapeutic strategies, advancing the precision oncology landscape.

• Lambda Protein Phosphatase: Precision in Phosphorylation Val

  2026-07-01

  Lambda Protein Phosphatase (RNase-free) from APExBIO sets a new standard for phosphorylation analysis, enabling high-confidence validation of phospho-specific antibodies and functional studies of regulatory protein modifications. Its robust dual-specificity and RNase-free purity streamline even the most challenging circadian and signaling workflows.

• Birinapant (TL32711): Enhancing Apoptosis Workflows in Cance

  2026-06-30

  Birinapant (TL32711) is a premier SMAC mimetic IAP antagonist, enabling precise induction of apoptosis and TRAIL sensitization in resistant cancer models. This article translates the latest reference study findings and hands-on protocols into actionable strategies for maximizing Birinapant's impact in apoptosis research.

• hiPSC-Derived Intestinal Organoids Advance Pharmacokinetics

  2026-06-30

  The referenced study establishes a direct 3D protocol for generating human induced pluripotent stem cell-derived intestinal organoids, offering a more physiologically relevant platform for pharmacokinetic studies. This innovation addresses longstanding limitations of traditional models and enables robust assessment of drug absorption and metabolism, with direct implications for benchmarking compounds such as Phenacetin.

• Ganetespib (STA-9090): Optimizing Hsp90 Inhibition in Cancer

  2026-06-29

  Ganetespib (STA-9090) delivers robust, selective Hsp90 inhibition, driving rapid degradation of oncogenic client proteins for advanced cancer research. This guide decodes practical workflows, troubleshooting tactics, and the latest cross-domain insights to maximize reproducibility and assay sensitivity using APExBIO’s trusted compound.

• UTP Solution: Precision Uridine-5'-triphosphate for RNA Assa

  2026-06-29

  UTP Solution (100 mM) empowers high-fidelity RNA synthesis and advanced gene expression studies with unmatched purity and workflow flexibility. Its DNase/RNase-free formulation from APExBIO ensures robust in vitro transcription and metabolic research, supporting nuanced experimental designs and rapid troubleshooting.

• Phillygenin Inhibits Inflammation and Apoptosis in Diabetic

  2026-06-28

  This study demonstrates that phillygenin, a natural lignan, significantly ameliorates diabetic nephropathy by targeting the TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β pathways to suppress inflammation and apoptosis. These mechanistic insights highlight phillygenin's potential as a novel therapeutic agent for diabetic kidney disease.

• Cytoskeleton Dependence in Mechanical Stress-Induced Autopha

  2026-06-27

  This study provides direct evidence that the cytoskeleton, especially microfilaments, is essential for mechanical stress-induced autophagy in human cells. The findings clarify how cytoskeletal components transduce mechanical signals to autophagic pathways, with important implications for research on cellular adaptation, mechanotransduction, and redox modulation.

• Moxidectin: Dual-Action Anthelmintic and Antifungal Potentia

  2026-06-26

  Explore the multifaceted benefits of moxidectin, a macrocyclic lactone anthelmintic, including its advanced use in parasitic worm control and novel synergy with antifungal agents. Uncover rigorous analysis and unique protocol insights not found in other reviews.

• HotStart™ 2X Green qPCR Master Mix: Technical Use Guide

  2026-06-26

  HotStart™ 2X Green qPCR Master Mix addresses specificity and reproducibility challenges in SYBR Green-based real-time PCR by minimizing non-specific amplification and primer-dimer formation. It is best suited for gene expression analysis, RNA-seq validation, and nucleic acid quantification. It is not recommended for applications requiring probe-based detection or multiplexed dye systems beyond SYBR Green and ROX.

• DAPI Solution (1 mg/mL): Advanced Strategies for Apoptosis a

  2026-06-25

  Explore the unique capabilities of DAPI Solution (1 mg/mL) for sensitive detection of apoptosis and cellular senescence, integrating new insights from macrophage-NP cell interactions. This article highlights advanced applications of DAPI in degenerative disease research and workflow optimization.

• YM-155 Hydrochloride: Precision Survivin Inhibitor Workflows

  2026-06-25

  YM-155 hydrochloride redefines survivin-targeted cancer research with nanomolar efficacy, empowering robust in vitro and in vivo assays for apoptosis and tumor regression. This guide translates the latest evidence into actionable workflows, advanced applications, and troubleshooting strategies, maximizing assay success and reproducibility.

• Gut Microbiota Absence Alters RPE/Choroid Transcriptome in A

  2026-06-24

  This study reveals that germ-free mice lacking gut microbiota display substantial transcriptomic changes in retinal pigment epithelium (RPE) and choroid tissues, implicating gut–retina interactions in age-related macular degeneration (AMD) pathogenesis. The findings highlight a novel gut–RPE/choroidal axis and suggest that microbiota may influence neovascular features of AMD.

• GPX3 Modulates Gemcitabine Sensitivity in Pancreatic Cancer

  2026-06-23

  This study demonstrates that glutathione peroxidase 3 (GPX3) acts as a tumor suppressor in pancreatic cancer by inhibiting the JNK/c-Jun signaling pathway, which in turn reduces cell proliferation, migration, invasion, and enhances chemosensitivity to gemcitabine. The findings provide mechanistic insight into overcoming chemoresistance in pancreatic cancer and suggest new avenues for precision therapy.

511 records 10/35 page Previous Next First page 上5页 678910 下5页 Last page